Screener
Xenon Pharmaceuticals XENE Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Xenon Pharmaceuticals’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338244
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Accounts payable and accrued liabilities (note 7) | $43,671 | $40,260 |
| Operating lease liability (note 6) | 1,338 | 1,532 |
| Total current liabilities | 45,009 | 41,792 |
| Operating lease liability, long-term (note 6) | 5,080 | 6,412 |
| Other liabilities, long-term | 3,287 | 3,199 |
| Total liabilities | $53,376 | $51,403 |
| Shareholders’ equity: | ||
| Common shares, without par value; unlimited shares authorized; issued and outstanding: 96,752,884 (December 31, 2025 - 80,010,790) (note 8) | $2,426,619 | $1,598,571 |
Item 1. Financial Statements
FAQ
- What is Xenon Pharmaceuticals's operating lease liabilities?
- Xenon Pharmaceuticals (XENE) reported operating lease liabilities of $5.08M in Q2 2026.
- How has Xenon Pharmaceuticals's operating lease liabilities changed year-over-year?
- Xenon Pharmaceuticals's operating lease liabilities decreased by 30.0% year-over-year, from $7.26M to $5.08M.
- What is the long-term trend for Xenon Pharmaceuticals's operating lease liabilities?
- Over 5 years (2020 to 2025), Xenon Pharmaceuticals's operating lease liabilities has grown at a 16.0% compound annual growth rate (CAGR), from $3.05M to $6.41M.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Xenon Pharmaceuticals's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude